Journey to Global STD
Clinical PK Studies
Genotoxic Impurity Test
Why Automation ?
Recruit and Welfare
BioInfra listed on KOSDAQ market
[Mar 02, 2023] BioInfra was listed on KOSDAQ market on March 2. Original article published on Yonhapnews Agency.
BioInfra aims to become the world's leading phase I clinical trial company.
[Feb 15, 2023] At the Biz invitation today, I met Lee Sang-deuk, CEO of BioInfras co., Ltd., a phase 1 clinical company that challenged the KOSDAQ market again.BioInfra is a c..
BioInfra wins Korea Value Management Award 2022
[Nov 23, 2022] BioInfra wins Korea Value Management Award 2022.Korea Value Management Awards are given to companies that derive new added value and corporate growth engines through innovati..
BioInfra’s 16th Business Report
We published our 16th business report. You can see it in the link below or download the attachment.
In the first half of 2023, many biotech companies try to list on the stock market again.
[Feb 08, 2023] Many biotech companies are preparing for initial public offerings in the first half of this year.When we examine these companies, “Gwontojungrae” becomes trend in biotec..
BioInfra secures global market on BE reliability
[Nov 23, 2022] BioInfra Co., Ltd., a contract research organization specialized in phase 1 clinical trials, will expand its business area based on analysis system technology. Original articl..
Challenge to breakthrough IPO
[Nov 14, 2022] There is another small company that is challenging to be listed on the stock market this month. It is BioInfra Co.,Ltd, a contract research organization(CRO) company.Ori..
BioInfra passes KOSDAQ eligibility
[Oct 13, 2022] The KOSDAQ Market division of the Korea Exchange announced on October 13 that it had approved the eligibility review for listing of Bioinfra Co., Ltd. Original article pu..